Granite Point Capital Management’s Acceleron Pharma XLRN Stock Holding History

Granite Point Capital Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-13,441	Closed	-$486K	–	100
2016 Q3	$486K	Sell	13,441 -1,500	-10%	-$49.7K	0.19%	71
2016 Q2	$508K	Buy	+14,941	New	+$486K	0.22%	68
2015 Q3	–	Sell	-11,358	Closed	-$359K	–	106
2015 Q2	$359K	Sell	11,358 -3,642	-24%	-$118K	0.1%	83
2015 Q1	$571K	Hold	15,000	–	–	0.21%	70
2014 Q4	$584K	Hold	15,000	–	–	0.27%	59
2014 Q3	$454K	Hold	15,000	–	–	0.23%	69
2014 Q2	$510K	Sell	15,000 -13,800	-48%	-$461K	0.35%	60
2014 Q1	$994K	Sell	28,800 -1,200	-4%	-$54.2K	0.71%	45
2013 Q4	$1.19M	Buy	+30,000	New	+$724K	0.2%	57

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return

Granite Point Capital Management's XLRN Position: Q4 2016 in Review

Granite Point Capital Management sold out of Acceleron Pharma (XLRN) in Q4 2016, closing a stake of 13,441 shares — an estimated $486K sold.

Granite Point Capital Management first reported a position in XLRN in Q4 2013 and held it in 9 quarters. The position peaked at $1.19M in Q4 2013. 146 funds tracked by Wall St. Rank hold XLRN as of Q4 2016.

Granite Point Capital Management reported no remaining Acceleron Pharma position as of Q4 2016 after selling out during the quarter.
Granite Point Capital Management sold 13,441 Acceleron Pharma shares in Q4 2016, an estimated $486K.
Granite Point Capital Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 9 quarters.
Granite Point Capital Management's Acceleron Pharma position peaked at $1.19M in Q4 2013.
146 funds tracked by Wall St. Rank held Acceleron Pharma as of Q4 2016.

Based on Granite Point Capital Management's 13F filing for Q4 2016, filed 7 Feb 2017.